

Journal Pre-proof



Invasive versus conservative management in spontaneous coronary artery dissection: a meta-analysis and meta-regression study

Pier Paolo Bocchino, MD, Filippo Angelini, MD, Luca Franchin, MD, M.D. Fabrizio d'Ascenzo, Federico Fortuni, MD, Ovidio De Filippo, MD, Federico Conrotto, MD, Fernando Alfonso, MD, Jacqueline Saw, MD, Javier Escaned, MD, Chengwei Liu, MD, Gaetano Maria De Ferrari, MD

PII: S1109-9666(21)00050-6

DOI: <https://doi.org/10.1016/j.hjc.2021.02.013>

Reference: HJC 619

To appear in: *Hellenic Journal of Cardiology*

Received Date: 2 November 2020

Revised Date: 2 January 2021


Accepted Date: 19 February 2021

Please cite this article as: Bocchino PP, Angelini F, Franchin L, Fabrizio d'Ascenzo M, Fortuni F, De Filippo O, Conrotto F, Alfonso F, Saw J, Escaned J, Liu C, De Ferrari GM, Invasive versus conservative management in spontaneous coronary artery dissection: a meta-analysis and meta-regression study, *Hellenic Journal of Cardiology*, <https://doi.org/10.1016/j.hjc.2021.02.013>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2021 Hellenic Society of Cardiology. Publishing services by Elsevier B.V. All rights reserved.

Invasive versus conservative management in spontaneous coronary artery dissection:
a meta-analysis and meta-regression study



Journal Pre-proof

1 **Invasive versus conservative management in spontaneous coronary artery dissection: a**
2 **meta-analysis and meta-regression study**

3

4 Pier Paolo Bocchino¹ MD, Filippo Angelini¹ MD, Luca Franchin¹ MD, Fabrizio d'Ascenzo¹
5 MD, Federico Fortuni² MD, Ovidio De Filippo¹ MD, Federico Conrotto¹ MD, Fernando
6 Alfonso³ MD, Jacqueline Saw⁴ MD, Javier Escaned⁵ MD, Chengwei Liu⁶ MD, Gaetano
7 Maria De Ferrari¹ MD

8 1. Division of Cardiology, Department of Medical Sciences, University of Turin, "Città della Salute e della
9 Scienza" hospital, Turin, Italy

10 2. Coronary Care Unit and Laboratory of Clinical and Experimental Cardiology, Fondazione IRCCS Policlinico
11 San Matteo, Pavia, Italy; Department of Molecular Medicine, University of Pavia, Pavia, Italy

12 3. Cardiology Department, Hospital Universitario de La Princesa, IIS-IP, Universidad Autónoma de Madrid.
13 CIBER-CV. Madrid. Spain.

14 4. Division of Cardiology, Vancouver General Hospital, Vancouver, British Columbia, Canada

15 5. Unidad de Cardiología Intervencionista, Hospital Clínico San Carlos, Madrid, Spain

16 6. Department of Cardiology, Wuhan Asia Hospital, Wuhan University of Science and Technology, Wuhan,
17 China.

18

19

20 **Short title:** Conservative vs invasive management for SCAD

21

22

23 **Conflicts of interest:** none declared

24

25

1 **Corresponding author:**

2 Pier Paolo Bocchino, MD

3 Department of Medical Sciences, Division of Cardiology, AOU Città della Salute e della Scienza, University of

4 Turin

5 Corso Bramante 88/90, 10126, Turin, Italy

6 Email: *pierpaolo1991@gmail.com*

7 Phone: +390116335570

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

Journal Pre-proof

1 **ABSTRACT**

2 **Background.** Data regarding the best treatment for spontaneous coronary artery dissection (SCAD) are scarce.

3 **The** aim of the present study was to compare the **clinical outcomes** of conservative *versus* invasive treatment in
4 SCAD patients.

5 **Methods.** We systematically searched the literature for studies evaluating the comparative efficacy and safety of
6 invasive revascularization *versus* medical therapy for the treatment of SCAD from 1990 to 2020. The study
7 endpoints were all-cause death, cardiovascular death, myocardial infarction, heart failure, SCAD recurrence and
8 target vessel revascularization (TVR) rates. Random-effect meta-analysis was performed comparing the clinical
9 outcomes between the two groups. A univariate meta-regression analysis was also performed.

10 **Results.** 24 observational studies with 1720 patients were included. After 28 ± 14 months, a conservative
11 approach was associated with **lower** TVR rate compared with invasive treatment (OR=0.50; 95%CI 0.28-0.90;
12 $P=0.02$). No statistical difference was found regarding all-cause death (OR=0.81; 95%CI 0.31–2.08; $P=0.66$),
13 cardiovascular death (OR=0.89; 95%CI 0.15–5.40; $P=0.89$), myocardial infarction (OR=0.95; 95%CI 0.50-1.81;
14 $P=0.87$), heart failure (OR 0.96; 95%CI 0.41–2.22; $P=0.92$) and SCAD recurrence (OR=0.94; 95%CI 0.52-1.72;
15 $P=0.85$). The meta-regression analysis suggested that male gender, diabetes mellitus, smoking habit, prior
16 coronary artery disease, left main coronary artery involvement, lower ejection fraction and low TIMI flow at
17 admission are related with higher overall mortality, whereas SCAD recurrence was higher among patients with
18 fibromuscular dysplasia.

19 **Conclusions.** A conservative approach was associated with similar clinical outcomes and lower TVR rates
20 compared ~~to~~ with an invasive strategy in SCAD patients; future prospective studies are needed to **confirm these**
21 **results**.

22

23 **Keywords:** spontaneous coronary artery dissection; SCAD; percutaneous coronary intervention;
24 revascularization; medical therapy.

25

1 INTRODUCTION

2 Spontaneous coronary artery dissection (SCAD) is defined as the acute development of a false lumen within the
3 coronary artery wall which is not secondary to iatrogenic nor traumatic insults.[1-2] Despite the true incidence
4 of SCAD is unknown due its frequent underdiagnosis, recent reports state that it may represent up to 4% of
5 angiographic studies performed for non-atherosclerotic acute coronary syndromes.[1-4] About 90% of SCAD
6 patients are women, with a high SCAD prevalence of 23% to 36% among young female patients presenting with
7 acute coronary syndromes.[1-7] Risk factors for SCAD include pregnancy and peri-partum periods, multiparity
8 (i.e. more than 3 births), fibromuscular dysplasia, connective tissue disorders, hormonal therapy and strong
9 mechanical and emotional stressors;[8-15] the correlation between SCAD and typical ischemic heart disease risk
10 factors remains to be elucidated.[12-16]

11 SCAD treatment is debated with case series and observational and retrospective studies reporting heterogeneous
12 outcomes.[3,4,7,11-18] The European Society of Cardiology position paper and the American Heart Association
13 Scientific Statement on SCAD favor a conservative strategy when revascularization is not mandatory due to
14 hemodynamic instability or ongoing ischemia;[1,2] this is mostly due to the suboptimal percutaneous coronary
15 intervention (PCI) success and the high risk of peri- and post-procedural complications in the setting of
16 SCAD.[12,16-18] Nevertheless, the best medical therapy and the role of invasive management are still a matter
17 of debate. Accordingly, the aim of the present study was to compare the **clinical outcomes** of conservative
18 versus invasive treatment in patients with SCAD.

19

20

21 METHODS

22

23 Study identification

24 We systematically searched MEDLINE/PubMed, Embase, the Cochrane database, Google Scholar,
25 www.tctmd.com, www.clinicaltrials.gov and www.clinicaltrialresults.org for randomized controlled trials
26 (RCTs) and observational studies that evaluated the comparative efficacy and safety of invasive
27 revascularization *versus* medical therapy for the treatment of SCAD from database inception to September 30,
28 2020. We excluded studies that investigated only iatrogenic or traumatic coronary artery dissections; studies not
29 providing differentiate sub-analyses for such types of dissections and SCAD were excluded as well.

1 To be eligible for inclusion, studies had to report on baseline characteristics of patients, procedural features and
2 at least one of the outcomes of interest.

3 Keywords used were “spontaneous coronary artery dissection” or “SCAD”. MeSH terms used were: “coronary
4 artery dissection, spontaneous”. Searches were limited to English language articles. Reference letters, reviews,
5 meta-analyses and editorials were also checked to identify potentially eligible studies. The process was
6 performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
7 and Meta-analysis Of Observational Studies in Epidemiology (MOOSE) statement.[19-20] The original study
8 protocol was registered on the PROSPERO platform (ID CRD42020166977).

9

10 **Study selection**

11 Three independent investigators (PPB, FA and LF) reviewed all titles and abstracts and selected the potentially
12 eligible ones. For each eligible study, full texts, supplementary materials and online appendices were examined
13 for inclusion/exclusion criteria, whereas their reference list was scanned to find other studies of potential
14 interest; discrepancies were resolved by consensus. When studies including a large population did not report
15 sufficient data of interest, the original dataset was requested to the respective authors for further specific sub-
16 analysis. Studies with fewer than 10 cases were excluded.

17

18 **Data extraction**

19 Data regarding study design, sample size, patients’ characteristics, clinical presentation, coronary angiography
20 findings, length of follow-up and outcomes of interest were extracted from the selected studies. SCAD was
21 categorized as type 1, 2 or 3 as described by Saw *et al.*,[12] when such data were available. The initial
22 management strategy (conservative *versus* invasive) was defined as the treatment decided at the time of
23 coronary angiography or within the next 24 hours when individual patient data were available. Discrepancies
24 were resolved by discussion and consensus among the authors.

25

26 **Endpoints**

27 The outcomes of interest were all-cause death, cardiovascular death, non-fatal myocardial infarction (MI), heart
28 failure (HF), target vessel revascularization (TVR) and SCAD recurrence. MI was defined as reported by each
29 included study. MI and HF events were considered eligible as efficacy outcomes only when occurring
30 throughout the follow-up period after the index-event at presentation according to the individual studies. TVR

1 was defined as PCI or coronary artery bypass grafting to the index SCAD-involved vessel at follow-up; the
2 initial attempted PCI procedure on the SCAD-involved vessel was thus excluded from the TVR definition.
3 SCAD recurrence was defined as new spontaneous dissection not involving extension of dissection of the
4 original SCAD lesion, unless otherwise specified in each article.[21]

5

6 **Statistical analysis**

7 Odds ratio (OR), mean difference and 95% confidence interval (CI) were obtained for each endpoint with a
8 random effect model. Heterogeneity between studies was assessed by measuring inconsistency using the I^2
9 index, which describes the percentage of total variation across the studies that is due to heterogeneity rather than
10 chance.[22] I^2 values of 25%, 50%, and 75% represented small, moderate and large amounts of heterogeneity,
11 respectively.

12 For the endpoints that were found out to be significantly different between the two groups, absolute risk
13 reduction and number needed to treat were calculated.

14 A leave-one-out sensitivity analysis was performed on the efficacy endpoints to evaluate if the results were
15 largely affected by single studies. The minimum number of subjects needed for a power of 80% with an alpha
16 error of 0.05 was assessed for each study outcome by comparing the incidence of individual events in each
17 treatment group. A sensitivity analysis on the study outcomes was also performed addressing studies published
18 before and after the Societies' position papers on SCAD in a separate fashion (i.e. prior to 2018 and after
19 2018).[1,2] The incidences of conservative *versus* invasive treatment strategies according to the clinical
20 presentation (ST-segment elevation MI vs non ST-segment elevation MI) and Thrombolysis in Myocardial
21 Infarction (TIMI) flow (grades 0-1 vs grades 2-3) were also compared, by means of Chi-square test.

22 A univariate meta-regression analysis for unadjusted log OR was also performed. The potential moderator effect
23 of age, sex, body mass index, arterial hypertension, diabetes mellitus (DM), prior or current smoking habit,
24 dyslipidemia, peripartum condition, fibromuscular dysplasia, prior coronary artery disease, ST-segment
25 elevation MI at presentation, left ventricular ejection fraction (LVEF) at presentation, left main coronary artery
26 involvement, multivessel disease, use of intracoronary imaging and TIMI flow grade 0 or 1 was explored.

27 The presence of eventual publication bias was assessed by funnel plot and Egger's regression test. Quality of
28 study assessment was performed by two independent investigators by means of the ROBINS-I tool:[23]
29 conflicts were resolved by consensus. The analyses were performed with Review Manager version 5.3

1 (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014), OpenMeta-Analyst version
2 beta 1.0 and Meta-Essentials.[24]

3

4 **RESULTS**

5

6 **Study and patient characteristics**

7 Overall, 1458 titles and abstracts were identified through database searching from database inception to
8 September 30, 2020; after exclusion according to pre-specified criteria, 24 studies were included in the present
9 analysis (Figure 1, Supplemental Table 1).[4,12,13,15,17,18,21,25-41] All the included studies were
10 observational. The work by Conrotto *et al.* did not report data on the overall study population, but patients'
11 clinical characteristics and outcomes were furnished by the author upon request and analyzed with the author's
12 permission.[35] SCAD was defined by angiography in all the selected studies with the optional use of additional
13 imaging techniques by some groups.

14 A total of 1720 patients were included: 1041 (61%) patients received medical therapy, whereas the remaining
15 679 (39%) patients underwent revascularization, be it either PCI (599 patients, 88%) or coronary artery bypass
16 grafting (81 patients, 12%). Mean follow-up time was 28 ± 14 months. 7 studies reported data regarding
17 fibromuscular dysplasia (FMD), which was present in 56% of the included patients;[12,13,15,18,21,31,39]
18 FMD had been actively screened for in 6 out of 7 studies but this piece of information is not specified in the
19 study by Tweet *et al.*[31] Supplemental Table 2 shows the main baseline characteristics for each study. Mean
20 age was 49 ± 5 years. 23% of patients were male and common cardiovascular risk factors were present in less
21 than half of the study population (arterial hypertension 39%, DM 8%, smoking habit 34%, dyslipidemia 31%).
22 Patients presented more frequently with acute coronary syndromes (ST-segment elevation MI 40%, non-ST-
23 segment elevation MI 48%, unstable angina 3%) and cardiac arrest was the clinical presentation in 6% of cases.
24 Mean LVEF at presentation was $53 \pm 5\%$. Type 2 SCAD was the main coronary angiography finding (63%), left
25 anterior descending (LAD) was the most affected coronary artery (51%) and a multivessel involvement was
26 present in 13% of patients. 35% of patients had lesions with TIMI flow grade 0 or 1 at presentation, while
27 lesions with flow grade 2 or 3 were present in 74% of patients (Supplemental Table 3).

28

29 **Endpoints**

1 After a mean follow-up of 28 ± 14 months all-cause death occurred in 15 (2.9%) patients in the medical treatment
2 group and in 24 (4.8%) patients in the revascularization group (OR 0.81; 95% CI 0.31–2.08; $P=0.66$) with a
3 moderate heterogeneity among the 20 studies (1048 patients) reporting this outcome ($I^2=33\%$) (Figure 2A).
4 Likewise, no statistical difference was found between conservative and invasive treatments regarding
5 cardiovascular death (OR 0.89; 95% CI 0.15–5.40; $P=0.89$), MI (OR 0.95; 95% CI 0.50-1.81; $P=0.87$), HF (OR
6 0.96; 95% CI 0.41–2.22; $P=0.92$) and SCAD recurrence (OR 0.94; 95% CI 0.52-1.72; $P=0.85$) (Figure 2B-E).

7 A total of 59 TVR events were recorded across the 11 studies (635 patients overall) assessing this outcome; 20
8 TVR events occurred in the medical therapy group and 39 in the invasive revascularization group. Medical
9 therapy was associated with a **significantly lower reduction of the** risk of TVR compared with invasive
10 revascularization (OR 0.50; 95% CI 0.28-0.90; $P=0.02$), ~~with an absolute risk reduction of 7.2% and a~~
11 ~~number needed to treat of 14~~ (Figure 2F).

12 Heterogeneity was unimportant among the studies as for the analyses on cardiovascular death, MI, HF, SCAD
13 recurrence and TVR ($I^2=0\%$).

14

15 Risk of bias assessment

16 The overall risk of bias was low in 12 (50%) studies, moderate in 11 (46%) studies and serious in 1 (4%) study.

17 The bias assessment for each study is shown in Supplemental Table 4. Visual assessment of the funnel plots and

18 Egger's regression test for TVR ($t\text{-test}=0.06$; $P=0.956$) did not show the presence of any publication bias

19 (Supplementary appendix, Figures S1 and S2).

20

21 Sensitivity analyses

22 The ORs remained stable in the leave-one-out analyses on cardiovascular death, MI, HF and SCAD recurrence.

23 The results on TVR became non-significant when the study by Tweet *et al.* was removed (OR 0.48; 95% CI

24 0.18-1.23; $P=0.13$) and marginally non-significant after excluding the study by Lettieri *et al.* (OR 0.56; 95% CI

25 0.30-1.01; $P=0.06$) (Supplemental Figure 3 and Supplemental Figure 4).[17,31]

26 The sensitivity analysis addressing studies published before and after the Societies' position statements on

27 SCAD separately showed that medical therapy was associated with a marginally significant lower all-cause

28 mortality compared to an invasive treatment before 2018 (OR 0.41; 95% CI 0.16-1.01, $P=0.05$), but a borderline

29 significant higher all-cause mortality from 2018 onward (OR 3.24; 95% CI 1.00-10.49; $P=0.05$); medical

30 therapy was associated with lower TVR rate before 2018 (OR 0.51; 95% CI 0.28-0.92; $P=0.02$), but only the

1 study by Kim et al. was available after 2018 assessing this endpoint;[40] no differences regarding the other
2 study outcomes were found (Supplemental Figure 5).

3 The number of patients treated conservatively or invasively according to the clinical presentation, namely ST-
4 segment elevation MI and non ST-segment elevation MI, was reported by twelve studies including 525 patients
5 overall;[4,13,17,26,27,30-32,34,36-38] an invasive strategy was pursued in 110 STEMI patients (62.2%)
6 compared to 82 (35.0%) NSTEMI patients ($P<0.001$). Eight studies reported the number of individual treatment
7 strategies according to TIMI flow rate for a total of 485 patients;[4,17,30-32,37,38,40] 126 (67.7%) patients
8 with TIMI flow grades 0 to 1 underwent revascularization as compared to 115 (38.5%) patients with TIMI flow
9 grades 2 to 3 ($P<0.001$) (Supplemental Table 5).

10

11 **Meta-regression analysis**

12 At meta-regression analysis male gender (β -coefficient: 0.001; $P<0.001$), DM (β -coefficient: 0.002; $P=0.002$),
13 smoking habit (β -coefficient: 0.001; $P<0.001$), history of coronary artery disease (β -coefficient: 0.003;
14 $P<0.001$), left main coronary artery involvement (β -coefficient: 0.003; $P<0.001$), lower LVEF at admission (β -
15 coefficient: -0.002; $P=0.014$) and low TIMI flow (β -coefficient: 0.001; $P=0.018$) were associated with a higher
16 rate of all-cause death (Figure 3). Smoking habit was related to a lower TVR rate (β -coefficient: -0.002;
17 $P=0.032$) and to a lower incidence of SCAD recurrence (β -coefficient: -0.002; $P<0.001$) (Supplemental Figure 6
18 and Supplemental Figure 7). On the contrary, FMD was associated with a higher recurrence of SCAD (β -
19 coefficient: 0.001; $P=0.019$), whereas DM was related with a lower SCAD recurrence rate (β -coefficient: -
20 0.006; $P=0.008$) (Supplemental Figure 6). Complete data regarding meta-regression analysis are reported in
21 Supplemental Table 6.

22

23 **DISCUSSION**

24 This study was conducted to compare the efficacy and safety of conservative and invasive strategies in patients
25 presenting with SCAD. This is the largest meta-analysis facing this issue to date and the first providing meta-
26 regression analysis. Our work suggests that invasive revascularization is associated with higher rates of TVR
27 than medical therapy with no significant difference in all-cause death, cardiovascular death, MI, HF and SCAD
28 recurrence rates after a mean follow-up of 28 ± 14 months.

1 SCAD management is challenging and treatment decisions are often taken by caring physicians based on
2 patients' clinical and angiographic characteristics on a case-by-case basis.[13,25-27,30,32] The European
3 Society of Cardiology position paper and the American Heart Association Scientific Statement on SCAD
4 recommend an initial conservative approach with medical therapy in hemodynamically stable patients without
5 ongoing signs or symptoms of ischemia;[1,2] this recommendation is based on data from previous observational
6 studies suggesting an increased risk of complications in the revascularization treatment group compared to
7 medically managed patients.[12,15,18,28,31,42] Nevertheless, no RCTs facing this issue exist to date. A
8 previous meta-analysis conducted by Martins *et al.* on a total population of 631 patients from 11 observational
9 studies showed that revascularization as the initial approach was associated with a marginally significant
10 increased risk of TVR compared to medical therapy (risk difference 0.06; 95% CI 0.01-0.11).[42] A most recent
11 meta-analysis by Jamil assessing the same issue and including 22 studies and 1435 patients did not find any
12 difference in one or other treatment strategy.[43] In line with previous studies,[42,43] we found no statistical
13 difference between conservative and invasive treatment strategies as for all-cause death, cardiovascular death,
14 MI, HF and SCAD recurrence; however, as the present analysis further extended to include 1720 patients, a
15 significant difference was found as for TVR, showing higher rates of TVR in the invasive treatment group as
16 compared to the conservative strategy.

17 An initial conservative strategy is supported by the high rates of spontaneous angiographic healing over few
18 months and by the fact that SCAD recurs mostly on vessels different from the original culprit coronary
19 artery.[11] PCI in the setting of SCAD is often laborious and its success rates are unsatisfactory. As a matter of
20 fact, in 8 out of the 17 studies from our analysis that reported on PCI success its rate was lower than 80% and
21 the overall mean PCI success rate was only 48%.[4,12,17,21,29,31-33] Moreover, literature data suggest that
22 only 30% of the PCI procedures performed in SCAD have long-lasting results at follow-up.[7] The procedural
23 and technical difficulties in this scenario should not be underestimated. In fact, there are several PCI-associated
24 risks such as entering the false vessel lumen with the guidewire, causing iatrogenic dissections and the
25 unpredictability of intramural hematoma shifting during angioplasty which can worsen the outcome.[1,2] This
26 latter issue is often underappreciated by angiography and it could be the very main driver of PCI failure.[31]
27 Intravascular imaging by means of intravascular ultrasound or optical coherence tomography might optimize
28 PCI and stent implantation in the setting of SCAD but its adoption for the diagnosis of SCAD in the setting of
29 acute coronary syndromes is fairly low, with only 65% of the studies included in the present analysis reporting
30 its use;[15,17,27-33,35-39] besides, intravascular imaging might be difficult to achieve in a dissected vessel due

1 to the high risk of misplacing the guidewire in the false lumen and subsequent iatrogenic dissection extension.
2 Therefore, when feasible, a conservative strategy seems the best initial approach whereas revascularization
3 therapy should be considered for patients presenting with incessant symptoms, arrhythmias and ongoing signs of
4 ischemia.

5 On the other hand, it must be acknowledged that the final reason for initial revascularization *versus* conservative
6 management remains difficult to capture in the original studies and this may represent a major bias (more
7 severe, aggressive, presentation in patients requiring revascularization) which, in turn, may partially explain the
8 results; as a matter of fact, if revascularization can provide similar clinical outcomes to those seen in patients
9 selected for conservative management, but in much more challenging patients, this would remain the strategy of
10 choice for this population. This might also explain the relatively high percentage (49%) of patients who had
11 undergone an invasive treatment, which might be due to the high prevalence of MI presentation with unreported
12 hemodynamic instability or ongoing signs of ischemia. The incidence of conservative *versus* invasive treatment
13 strategies according to clinical presentation and TIMI flow rate reported more frequent revascularizations in
14 patients admitted with ST-segment elevation MI compared to non ST-segment elevation MI and in patients with
15 low compared to high TIMI flow, suggesting that the initial patient's conditions might indeed play a role in the
16 operator's decision to pursue an invasive *versus* a conservative treatment strategy. Moreover, revascularization
17 might have been performed selectively in patients with extensive SCAD involvement of the coronary arteries
18 (e.g., left main SCAD extending into left anterior descending and circumflex coronary arteries) requiring high
19 total stent length, and revascularization may protect against severe adverse outcomes at the cost of increased
20 TVR in these ominous scenarios.

21 The best conservative management remains unclear in the setting of SCAD as no studies have compared
22 different pharmacological strategies to date. Our study shows that acetylsalicylic acid is most commonly used in
23 this scenario and clopidogrel is mostly favored over potent P2Y12 inhibitors when a dual antiplatelet regimen is
24 commenced.[13,15,17,21,26,28-30,34-37] Dual antiplatelet therapy with acetylsalicylic acid and clopidogrel
25 seems appropriate in the acute phase independently from the treatment strategy due to the frequent presence of a
26 luminal thrombus in the dissected coronary artery demonstrated by optical coherence tomography
27 studies.[1,11,21,29]

28 Meta-regression data suggest that male gender, DM, prior or current smoking habit, coronary artery disease
29 history, left main coronary artery involvement, lower LVEF and low TIMI flow at admission are related with

1 higher risk of overall death; this may be due to the higher mortality related with these concomitant conditions as
2 well as to the greater prevalence of cardiovascular risk factors in men compared to women at the same young
3 age. SCAD recurrence was higher among FMD patients, as previous studies already suggested.[10,11]
4 Interestingly, smoking habit was associated with lower TVR rate and SCAD recurrence seems to be lower in
5 smokers and DM patients. These results resemble the paradoxical apparent protective roles of smoking in acute
6 coronary syndromes or DM in Takotsubo syndrome;[45,46] nevertheless, study biases need to be considered
7 when exploring these results, which must be viewed as hypothesis-generating rather than definitive.

8

9 **Limitations**

10 There are some limitations to this study. First, only observational studies could be included in the analysis and
11 most of them were retrospective. Each study carries intrinsic selection biases invariably associated with patients'
12 own characteristics, operators' preferences at the time of revascularization and different SCAD treatment
13 approaches in individual centers; the wide variability in sample sizes and follow-up times across the studies
14 implies another limitation of the present work, as suggested by the results of the leave-one-out analyses. Since
15 this research encompasses works published since 1994, another study bias comes from changes in treatment
16 decisions over time due to advances both in invasive procedures and in pharmacological science. The study
17 results were derived from univariate analyses and the potential biases coming from this approach must be
18 considered as well. Moreover, only the TVR analysis was sufficiently powered to detect differences between
19 conservative and invasive treatment strategies. Overall event rate was low and the absence of significant
20 difference between the two strategies regarding the other efficacy outcomes might be due to the relatively small
21 sample size of the study population rather than a real lack of statistical difference between treatments. The
22 number of patients undergoing coronary artery bypass grafting was low and no definite conclusion could be
23 drawn on this specific population. Peripartum period definition was not clearly reported in the component
24 studies and different "peripartum" time intervals might have been considered. Patients' screening for FMD
25 varied in individual studies and results on FMD patients might have affected by such heterogeneity. A potential
26 selection bias should also be considered, as patients selected for PCI might have been sicker than patients being
27 offered medical therapy, as previously discussed; unfortunately, the included studies did not provide separate
28 data on **the study outcomes** in conservative vs invasive groups according to the initial presentation or TIMI
29 **flow and the impact of these variables on the relative benefit of invasive versus conservative approach**

1 **could not be assessed.** Lastly, the results of the sensitivity analyses and the meta-regression results might have
2 been affected by the small number of the included studies and unmeasured confounding factors and they must
3 be interpreted with caution.

4

5 **Conclusions**

6 This meta-analysis corroborates previous data on SCAD management suggesting that a conservative first-line
7 approach is associated with similar results to invasive treatment in terms of long-term survival, MI, HF and
8 SCAD recurrence, but is associated with a significantly lower incidence of TVR. Larger prospective studies and
9 RCTs are needed to confirm these results and better clarify the best initial approach in SCAD patients.

10

11 **Acknowledgements:** none.

12 **Funding:** This research received no specific grant from any funding agency in the public, commercial, or not-
13 for-profit sectors

14

15

16

17 **REFERENCES**

18 1 Adlam D, Alfonso E, Maas A, Vrints C; Writing Committee. European Society of Cardiology, acute
19 cardiovascular care association, SCAD study group: a position paper on spontaneous coronary artery dissection.

20 *Eur Heart J* 2018;39(36):3353–3368

21 2 Hayes SN, Kim ESH, Saw J, et al. Spontaneous Coronary Artery Dissection: Current State of the Science: A
22 Scientific Statement From the American Heart Association. *Circulation* 2018;137(19):e523-e557

23 3 Nishiguchi T, Tanaka A, Ozaki Y, et al. Prevalence of spontaneous coronary artery dissection in patients with
24 acute coronary syndrome. *Eur Heart J Acute Cardiovasc Care* 2016;5:263–270.

- 1 4 Vanzetto G, Berger-Coz E, Barone-Rochette G, et al. Prevalence, therapeutic management and medium-term
2 prognosis of spontaneous coronary artery dissection: results from a database of 11,605 patients. *Eur J*
3 *Cardiothorac Surg* 2009;35:250–254.
- 4 5 Elkayam U, Jalnapurkar S, Barakkat MN, et al. Pregnancy-associated acute myocardial infarction: A review of
5 contemporary experience in 150 cases between 2006 and 2011. *Circulation* 2014;129:1695–1702
- 6 6 Motreff P, Malcles G, Combaret N, et al. How and when to suspect spontaneous coronary artery dissection:
7 novel insights from a single-centre series on prevalence and angiographic appearance. *EuroIntervention*
8 2017;12:e2236–e2243.
- 9 7 Saw J, Aymong E, Mancini GB, et al. Nonatherosclerotic coronary artery disease in young women. *Can J*
10 *Cardiol* 2014;30:814–819.
- 11 8 Havakuk O, Goland S, Mehra A, Elkayam U. Pregnancy and the risk of spontaneous coronary artery
12 dissection: an analysis of 120 contemporary cases. *Circ Cardiovasc Interv* 2017;10:e004941.
- 13 9 Faden MS, Bottega N, Benjamin A, Brown RN. A nationwide evaluation of spontaneous coronary artery
14 dissection in pregnancy and the puerperium. *Heart* 2016;102:1974–1979.
- 15 10 Prasad M, Tweet MS, Hayes SN, et al. Prevalence of extracoronary vascular abnormalities and fibromuscular
16 dysplasia in patients with spontaneous coronary artery dissection. *Am J Cardiol* 2015;115:1672–1677.
- 17 11 Saw J, Ricci D, Starovoytov A, Fox R, Buller CE. Spontaneous coronary artery dissection: prevalence of
18 predisposing conditions including fibromuscular dysplasia in a tertiary center cohort. *JACC Cardiovasc Interv*
19 2013;6:44–52.
- 20 12 Saw J, Aymong E, Sedlak T, et al. Spontaneous coronary artery dissection: association with predisposing
21 arteriopathies and precipitating stressors and cardiovascular outcomes. *Circ Cardiovasc Interv* 2014;7:645–655.
- 22 13 McGrath-Cadell L, McKenzie P, Emmanuel S, et al. Outcomes of patients with spontaneous coronary artery
23 dissection. *Open Heart* 2016;3:e000491.
- 24 14 Fahmy P, Prakash R, Starovoytov A, Boone R, Saw J. Pre-disposing and precipitating factors in men with
25 spontaneous coronary artery dissection. *JACC Cardiovasc Interv* 2016;9:866–868

- 1 15 Nakashima T, Noguchi T, Haruta S, et al. Prognostic impact of spontaneous coronary artery dissection in
2 young female patients with acute myocardial infarction: a report from the Angina Pectoris-Myocardial
3 Infarction Multicenter Investigators in Japan. *Int J Cardiol* 2016;207:341–348.
- 4 16 Tweet MS, Hayes SN, Pitta SR, et al. Clinical features, management, and prognosis of spontaneous coronary
5 artery dissection. *Circulation* 2012;126:579–588.
- 6 17 Lettieri C, Zavalloni D, Rossini R, et al. Management and Long-Term Prognosis of Spontaneous Coronary
7 Artery Dissection. *Am J Cardiol* 2015;116(1):66-73.
- 8 18 Rogowski S, Maeder MT, Weilenmann D, et al. Spontaneous Coronary Artery Dissection: Angiographic
9 Follow-Up and Long-Term Clinical Outcome in a Predominantly Medically Treated Population. *Catheter*
10 *Cardiovasc Interv* 2017;89(1):59-68.
- 11 19 Moher D, Liberati A, Tetzlaff J, Altman DG; The PRISMA Group. Preferred Reporting Items for Systematic
12 Reviews and Meta-Analyses: The PRISMA Statement. *BMJ* 2009;339:b2535
- 13 20 Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of Observational Studies in Epidemiology: A
14 Proposal for Reporting. *JAMA* 2000;283(15):2008-2012
- 15 21 Saw J, Humphries K, Aymong E, et al. Spontaneous Coronary Artery Dissection: Clinical Outcomes and
16 Risk of Recurrence. *J Am Coll Cardiol* 2017;70(9):1148-1158
- 17 22 Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analysis. *BMJ*
18 2003;327(7414):557-560.
- 19 23 Sterne JAC, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomized
20 studies of interventions. *BMJ* 2016; 355; i4919
- 21 24 Suurmond R, van Rhee H, Hak T. Introduction, comparison and validation of Meta-Essentials: A free and
22 simple tool for meta-analysis. *Res Synth Methods* 2017;8:537-553.
- 23 25 Jorgensen MB, Aharonian V, Manskhani P, Mahrer PR. Spontaneous coronary dissection: a cluster of cases
24 with this rare finding. *Am Heart J* 1994;127:1382-1387.
- 25 26 Mortensen KH, Thuesen L, Kristensen IB, Christiansen EH. Spontaneous Coronary Artery Dissection: A
26 Western Denmark Heart Registry Study. *Catheter Cardiovasc Int* 2009;74:710-717.

- 1 27 Ito H, Taylor L, Bowman M, Fry ETA, Hermiller JB, Van Tassel JW. Presentation and Therapy of
2 Spontaneous Coronary Artery Dissection and Comparisons of Postpartum Versus Nonpostpartum Cases. *Am J*
3 *Cardiol* 2011;107:1590–1596.
- 4 28 Alfonso F, Paulo M, Lennie V, et al. Spontaneous coronary artery dissection: Long-term follow-up of a large
5 series of patients prospectively managed with a ‘conservative’ therapeutic strategy. *J Am Coll Cardiol Intv*
6 2012;5:1062–1070.
- 7 29 Alfonso F, Paulo M, Gonzalo N, et al. Diagnosis of Spontaneous Coronary Artery Dissection by Optical
8 Coherence Tomography. *J Am Coll Cardiol* 2012;59:1073–1079.
- 9 30 Buja P, Coccato M, Fraccaro C, et al. Management and outcome of spontaneous coronary artery dissection:
10 Conservative therapy versus revascularization. *Int J Cardiol* 2013; 168: 2907-2908.
- 11 31 Tweet MS, Eleid MF, Best PJ, et al. Spontaneous coronary artery dissection: Revascularization versus
12 conservative therapy. *Circ Cardiovasc Interv* 2014; 7: 777-786
- 13 32 Sultan A, Kreutz RP. Variations in clinical presentation, risk factors, treatment, and prognosis of spontaneous
14 coronary artery dissection. *J Invasive Cardiol* 2015; 27(8):363-369.
- 15 33 Roura G, Ariza-Sole A, Rodriguez-Caballero IF, et al. Noninvasive follow-up of patients with spontaneous
16 coronary artery dissection with CT angiography. *J Am Coll Cardiol Imaging* 2016; 9: 896-897.
- 17 34 Godinho AR, Vasconcelos M, Araújo V, Maciel MJ. Spontaneous Coronary Artery Dissection in Acute
18 Coronary Syndrome: Report of a Series of Cases with 17 Patients. *Arq Bras Cardiol* 2016;107(5):491-494.
- 19 35 Conrotto F, D’Ascenzo F, Cerrato E, et al. Safety and efficacy of drug eluting stents in patients with
20 spontaneous coronary artery dissection. *Int J Cardiol* 2017;238:105-109.
- 21 36 Cade JR, Szarf G, de Siqueira ME, et al. Pregnancy-associated spontaneous coronary artery dissection:
22 insights from a case series of 13 patients. *Eur Heart J Cardiovasc Imaging* 2017;18(1):54-61.
- 23 37 Abreu G, Galvão Braga C, Costa J, Azevedo P, Marques J. Spontaneous coronary artery dissection: a single-
24 center case series and literature review. *Rev Port Cardiol* 2018;37(8):707-713.
- 25 38 Lobo AS, Cantu SM, Sharkey SW, et al. Revascularization in Patients With Spontaneous Coronary Artery
26 Dissection and ST-Segment Elevation Myocardial Infarction. *J Am Coll Cardiol* 2019;74(10):1290-1300.

- 1 39 Macaya F, Moreu M, Ruiz-Pizarro V, et al. Screening of extra-coronary arteriopathy with magnetic
2 resonance angiography in patients with spontaneous coronary artery dissection: a single-centre experience.
3 *Cardiovasc Diagn Ther* 2019;9(3):229-238.
- 4 40 Kim Y, Han X, Ahn Y, et al. Clinical characteristics of spontaneous coronary artery dissection in young
5 female patients with acute myocardial infarction in Korea. *Korean J Intern Med* 2019 Jul 18
- 6 41 Liu X, Xu C, Liu C, Su X. Clinical characteristics and long-term prognosis of spontaneous coronary artery
7 dissection: A single-center Chinese experience. *Pak J Med Sci* 2019;35(1):106-112.
- 8 42 Martins JL, Afreixo V, Santos L, Costa M, Santos J, Gonçalves L. Medical treatment or revascularisation as
9 the best approach for spontaneous coronary artery dissection: A systematic review and meta-analysis. *Eur Heart*
10 *J Acute Cardiovasc Care* 2018;7(7):614-623
- 11 43 Jamil A, Tajrishi FZ, Kahe F, et al. Spontaneous coronary artery dissection managed with a conservative or
12 revascularization approach: a meta-analysis. *J Cardiovasc Med (Hagerstown)* 2020;21(1):42-50
- 13 44 Sharma S, Kaadan MI, Duran JM, et al. Risk Factors, Imaging Findings, and Sex Differences in Spontaneous
14 Coronary Artery Dissection. *Am J Cardiol* 2019;123:1783–1787
- 15 45 Aune E, Røislien J, Mathisen M, Thelle DS, Otterstad JE. The "smoker's paradox" in patients with acute
16 coronary syndrome: a systematic review. *BMC Med* 2011;9:97
- 17 46 Bill V, El-Battrawy I, Behnes M, et al. "Diabetes paradox" in Takotsubo Cardiomyopathy. *Int J*
18 *Cardiol* 2016;224:88-89.

19

20


21 **FIGURE LEGENDS**

22 **Figure 1:** Flow-chart describing the screening and selection of the included studies.

23 **Figure 2:** Forest plot event-rates of all-cause death (A), cardiovascular death (B), myocardial infarction (C),
24 heart failure (D), recurrent spontaneous coronary artery dissection (E) and target vessel revascularization (F).
25 CI, confidence interval; MT, medical therapy; Revasc, revascularization; SCAD, spontaneous coronary artery
26 dissection.


1 **Figure 3:** Meta-regression analysis graphs describing the effects of male gender (A), diabetes mellitus (B), prior
2 or current smoking habit (C), prior coronary artery disease (D), initial ejection fraction (E), left main coronary
3 artery territory involvement (F) and TIMI flow (G) on the proportion of all-cause mortality. CAD, coronary
4 artery disease; CI, confidence interval; DM, diabetes mellitus; EF, ejection fraction; SE, standard error; TIMI,
5 Thrombolysis In Myocardial Infarction.

Journal Pre-proof




Journal Pre-proof


A. All-cause death




B. Cardiovascular death




C. Myocardial infarction



D. Heart failure



E. Recurrent SCAD



F. Target vessel revascularization

